Antiepileptic drugs: Eslicarbazepine for use as adjunctive treatment of partial-onset seizures


Aptiom ( Eslicarbazepine acetate ) is a prescription medicine used with other medicines to treat partial-onset seizures.

Aptiom, a voltage-gated sodium channel inhibitor, is a prescription medicine approved for use as adjunctive treatment of partial-onset seizures. Treatment with Aptiom should be initiated at 400 mg once daily. After one week, dosage may be increased to the recommended maintenance dosage of 800 mg once daily. Some patients may benefit from the maximum recommended maintenance dosage of 1,200 mg once daily, although this dosage is associated with an increase in adverse reactions. The maximum dose of 1,200 mg daily should only be initiated after the patient has tolerated 800 mg daily for at least a week.
For some patients, treatment may be initiated at 800 mg once daily if the need for additional seizure reduction outweighs an increased risk of adverse reactions during initiation.

Important safety information

Aptiom is contraindicated in patients who are allergic to Eslicarbazepine acetate, any of the other ingredients in Aptiom or Oxcarbazepine.

Eslicarbazepine may cause:

a) suicidal thoughts or actions, depression or mood problems;

b) serious skin rash or other serious allergic reactions, which may affect organs or other parts of your body like the liver or blood cells. Some symptoms may include: swelling of the face, eyes, lips or tongue, trouble swallowing or breathing, yellowing of the skin or eyes or severe fatigue or weakness.

c) level of sodium in the blood to be low. Symptoms may include nausea, tiredness, lack of energy, irritability, confusion, muscle weakness or muscle spasms, or more frequent or more severe seizures.

d) problems that can affect the nervous system including dizziness, sleepiness, vision problems and difficulties with coordination and balance.

e) problems that can affect the liver. Symptoms of liver problems include yellowing of your skin or the whites of your eyes and nausea or vomiting.

Eslicarbazepine may slow the thinking or the motor skills. The patient should not drive or operate heavy machinery until he knows how.

To stop Aptiom suddenly can cause serious problems.

The most common side effects in patients taking Aptiom include dizziness, sleepiness, nausea, headache, double vision, vomiting, feeling tired, problems with coordination, blurred vision and shakiness. ( Xagena )

Souce: Sunovion Pharmaceuticals, 2013

XagenaMedicine_2013



Indietro

Altri articoli

The FDA ( U.S. Food and Drug Administration ) has approved XCopri ( Cenobamate tablets ) to treat partial-onset seizures...


The FDA ( U.S. Food and Drug Administration ) has approved Xcopri ( Cenobamate tablets ) to treat partial-onset seizures...


The positive results of the first pivotal phase 3 study of the investigational medicine Epidiolex ( Cannabidiol or CBD )...


The aim of a study was to evaluate the efficacy and safety of the new antiepileptic drug Brivaracetam ( Briviact...


Brivaracetam ( UCB 34714; Briviact ) is an add-on treatment for adult patients with partial seizures. Similar to Levetiracetam (...


In February 2014, the American Heart Association [ AHA ] /American Stroke Association [ ASA ] released their first guideline...


Preliminary efficacy and safety data on 27 children and young adults with treatment-resistant epilepsy who have been treated with an...


A phase III clinical trial ( Study 332 ) of AMPA receptor antagonist Perampanel ( Fycompa ) has met its...


A study ( Study 307 ) has evaluated safety, tolerability, seizure frequency, and regional variations in treatment responses with the...


Sudden unexpected death in epilepsy ( SUDEP ) is the leading cause of death in people with chronic refractory epilepsy....